Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Noshir Anthony Dacosta"'
Autor:
Agostina Stradella, Joanne L. Blum, Sung-Bae Kim, Lee S. Schwartzberg, Sara M. Tolaney, Thomas Wei, Hope S. Rugo, Stew Kroll, Yin-Hsun Feng, Igor Bondarenko, Yann Izarzugaza, Mafalda Oliveira, Noshir Anthony Dacosta, Arlene Chan, Michel Pavic, Mei-Ching Liu, Maria Eva Peréz Lopéz, Elizabeth A. Mittendorf, Samuel Guan Wei Ow, Joe O'Connell
Publikováno v:
Cancer Research. 80:OT1-08
Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Yann Izarzugaza, Gavin Marx, Igor Bondarenko, Andrew D. Seidman, Mafalda Oliveira, Lee S. Schwartzberg, Joe O'Connell, Yin-Hsun Feng, Sung-Bae Kim, Y.S. Chae, Hope S. Rugo, Julie Lemieux, Joyce O'Shaughnessy, Thomas Wei, Jamil Asselah, Noshir Anthony Dacosta, Mei-Ching Liu, Gail S. Wright
Publikováno v:
Cancer Research. 80:OT1-08
Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Yaroslav Shparyk, Andrew D. Seidman, Yee Soo Chae, Lee S. Schwartzberg, Thomas Wei, Yevhen Hotko, Yen-Shen Lu, Sina Vatandoust, Sara M. Tolaney, Noshir Anthony Dacosta, Sabela Recalde, Chi-Feng Chung, Igor Bondarenko, Hope S. Rugo, Nuria Chic, Patricia Gomez, Joyce O'Shaughnessy, Joe O'Connell, Lawrence Panasci, Gail Lynn Shaw Wright
Publikováno v:
Journal of Clinical Oncology. 39:1061-1061
1061 Research Funding: Odonate Therapeutics, Inc. Background: T is a novel, oral taxane with unique properties, including: oral administration with a low pill burden, a long (8-day) half-life in humans, once-every-3-weeks dosing, no observed hypersen
Autor:
Haythem Ali, RA Fleming, Joel R. Eisner, William R. Moore, Aditya Bardia, SJ Lemon, Anthony D. Elias, TA Traina, Ayca Gucalp, Michael A. Danso, Nashat Y. Gabrail, Kurman, Noshir Anthony Dacosta, Elizabeth C. Riley
Publikováno v:
Cancer Research. 77:P2-08
Background: Seviteronel (Sevi), a CYP17-lyase (L) inhibitor (reduces testosterone (T) and estradiol (E2) biosynthesis) and a competitive AR antagonist, has activity in castration resistant prostate cancer at a dose of 600mg nightly. Sevi potently inh
Autor:
Noshir Anthony Dacosta, Yann Izarzugaza, Joanne L. Blum, MC Liu, Elizabeth A. Mittendorf, Samuel Guan Wei Ow, Thomas Wei, Igor Bondarenko, Lee S. Schwartzberg, Sara M. Tolaney, Mafalda Oliveira, Hope S. Rugo, Agostina Stradella, M.E. Perez Lopez, Michel Pavic, S.-B. Kim, Stew Kroll, Yin-Hsun Feng, Joe O'Connell, A. Chan
Publikováno v:
Annals of Oncology. 30:v138-v139
Background Chemotherapy (CT) treatments with robust efficacy that preserve quality of life are needed. Tesetaxel (T) is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pil
Autor:
Igor Bondarenko, Gun Min Kim, Lee S. Schwartzberg, Sara M. Tolaney, Thomas Wei, Agostina Stradella, Mei-Ching Liu, Yen-Shen Lu, Joe O'Connell, Vance Wright-Browne, Samuel Guan Wei Ow, Tira Jing Ying Tan, Hope S. Rugo, Noshir Anthony Dacosta, Yann Izarzugaza, Arlene Chan, Elizabeth A. Mittendorf, Maria Eva Perez, Mafalda Oliveira, Michel Pavic
Publikováno v:
Journal of Clinical Oncology. 38:TPS1111-TPS1111
TPS1111 Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. T is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Joel R. Eisner, Aditya Bardia, William R. Moore, Stephen J. Lemon, Tiffany A. Traina, Ronald A. Fleming, Nashat Y. Gabrail, Noshir Anthony Dacosta, Michael R Kurman, Ayca Gucalp, Haythem Ali, Michael A. Danso
Publikováno v:
Journal of Clinical Oncology. 34:1088-1088
1088Background: Seviteronel (Sevi), a CYP17-L inhibitor (reduces androgen and estrogen biosynthesis) and AR antagonist, has activity in castration resistant prostate cancer (CRPC) at a dose of 750 mg nightly. Sevi potently and dose-dependently inhibi
Autor:
Joanne L. Blum, Linda T. Vahdat, Jonathan L. Wright, John W. Smith, Nicole Meneses, Antoinette R. Tan, Ragene Rivera, Noshir Anthony Dacosta, Kumari Chandrawansa, Elizabeth Tan-Chiu, Fang Fang, Ellen Chuang, Brian Pruitt, Dale E. Shuster, David Smith, Patricia E. Cole, Joyce O'Shaughnessy, Simon Ashworth, Carol J. Fabian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(18)
Purpose Eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analog of the marine natural product halichondrin B. This open-label, single-arm, phase II study evaluated efficacy and tolerabilit